Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:BTAI NASDAQ:OMER NASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.80-2.0%$0.84$0.55▼$2.22$10.14M1.51103,584 shs107,473 shsBTAIBioXcel Therapeutics$1.41+0.7%$1.19$1.01▼$8.08$43.23M0.3614,481 shs345,946 shsOMEROmeros$9.51-4.0%$11.77$2.95▼$17.65$717.24M2.522.40 million shs1.94 million shsRAPTRapt Therapeutics$58.02$57.90$5.67▼$58.02$1.61B0.494.25 million shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-2.04%-3.10%-10.12%+14.00%-52.53%BTAIBioXcel Therapeutics+0.71%+11.90%+20.51%+15.57%-22.10%OMEROmeros-4.04%-9.26%-13.86%-21.27%+217.00%RAPTRapt Therapeutics0.00%0.00%0.00%0.00%+625.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.80-2.0%$0.84$0.55▼$2.22$10.14M1.51103,584 shs107,473 shsBTAIBioXcel Therapeutics$1.41+0.7%$1.19$1.01▼$8.08$43.23M0.3614,481 shs345,946 shsOMEROmeros$9.51-4.0%$11.77$2.95▼$17.65$717.24M2.522.40 million shs1.94 million shsRAPTRapt Therapeutics$58.02$57.90$5.67▼$58.02$1.61B0.494.25 million shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-2.04%-3.10%-10.12%+14.00%-52.53%BTAIBioXcel Therapeutics+0.71%+11.90%+20.51%+15.57%-22.10%OMEROmeros-4.04%-9.26%-13.86%-21.27%+217.00%RAPTRapt Therapeutics0.00%0.00%0.00%0.00%+625.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07406.88% UpsideBTAIBioXcel Therapeutics 2.25Hold$11.00680.14% UpsideOMEROmeros 2.83Moderate Buy$38.00299.58% UpsideRAPTRapt Therapeutics 2.15Hold$48.44-16.50% DownsideCurrent Analyst Ratings BreakdownLatest BTAI, APRE, OMER, and RAPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $33.006/10/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/2/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/14/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Hold (C-)5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/14/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/21/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OMEROmeros D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.004/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BTAIBioXcel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K34.25N/AN/A$1.52 per share0.53BTAIBioXcel Therapeutics$640K68.03N/AN/A($4.37) per share-0.32OMEROmerosN/AN/A$1.80 per share5.29($1.71) per shareN/ARAPTRapt TherapeuticsN/AN/AN/AN/A$11.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)BTAIBioXcel Therapeutics-$69.90M-$5.75N/AN/AN/A-11,078.53%N/A-201.53%8/11/2026 (Estimated)OMEROmeros-$3.35M$0.7013.59135.86N/AN/A-102.16%64.87%8/13/2026 (Estimated)RAPTRapt Therapeutics-$129.87M-$11.06N/AN/AN/AN/A-61.81%-54.73%N/ALatest BTAI, APRE, OMER, and RAPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325-$0.54-$0.0075-$0.54$0.38 million$0.21 million5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A5/13/2026Q1 2026OMEROmeros-$0.40-$0.24+$0.16$0.62$4.19 million$9.89 million3/31/2026Q4 2025OMEROmeros-$0.55$3.14+$3.69$0.98$40.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92BTAIBioXcel TherapeuticsN/A0.620.61OMEROmerosN/A3.033.03RAPTRapt TherapeuticsN/A12.0412.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%BTAIBioXcel Therapeutics30.68%OMEROmeros48.79%RAPTRapt Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics10.49%BTAIBioXcel Therapeutics3.70%OMEROmeros10.50%RAPTRapt Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataBTAIBioXcel Therapeutics9030.88 million29.74 millionNo DataOMEROmeros21072.38 million64.78 millionOptionableRAPTRapt Therapeutics8027.71 million27.06 millionOptionableBTAI, APRE, OMER, and RAPT HeadlinesRecent News About These CompaniesFTC drug divestiture policy may reduce competition, study findsApril 10, 2026 | news-medical.netNThis Biotech Was Quietly Bought Before a $58 Per Share TakeoutMarch 21, 2026 | fool.comRAPT Therapeutics Completes Acquisition and Transitions to Private OwnershipMarch 18, 2026 | theglobeandmail.comThis Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per ShareMarch 15, 2026 | fool.comGSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth StoryMarch 7, 2026 | finance.yahoo.comGSK reached out to buyout target's big shareholder before talking to senior leadersMarch 5, 2026 | bizjournals.comAssessing RAPT Therapeutics (RAPT) Valuation After A Sharp 3 Month Share Price SurgeMarch 1, 2026 | finance.yahoo.comThis Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer EmergesFebruary 25, 2026 | fool.comGSK to buy Canada's 35Pharma for $950 millionFebruary 25, 2026 | finance.yahoo.comGSK’s $2.2 billion RAPT acquisition shows how a constrained immunology use case can become adoption ready and commercially attractiveFebruary 10, 2026 | businessweekly.co.ukBThe Pharma Letter M&A round-up - January 2026February 6, 2026 | thepharmaletter.comTRAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPTFebruary 5, 2026 | businesswire.comRAPT Therapeutics (RAPT) price target decreased by 12.94% to 54.97February 4, 2026 | msn.comJan. 27 Business Watch: Vioneo moves project to China; GSK to buy Rapt Therapeutics for $2.2 billionJanuary 28, 2026 | cen.acs.orgCHalper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their RightsJanuary 27, 2026 | globenewswire.comAssessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price SurgeJanuary 23, 2026 | finance.yahoo.comBiggest Market Mover: RAPT Therapeutics Stock Soars After GSK $2.2B Acquisition DealJanuary 21, 2026 | finance.yahoo.comRAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPTJanuary 21, 2026 | businesswire.comGSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT BuyoutJanuary 21, 2026 | zacks.comRapt Therapeutics (RAPT) Stock: Pharma Giant GSK Pays $2.2 Billion for BiotechJanuary 21, 2026 | blockonomi.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe SpaceX Sell-Off May Be More Than a Market OverreactionBy Jeffrey Neal Johnson | June 24, 2026The 127-Gigawatt Problem: Why AI Needs Its Own PowerBy Jeffrey Neal Johnson | June 12, 2026SpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026How Does D-Wave's New Simulator Change the Quantum Computing Landscape?By Nathan Reiff | June 23, 2026AirJoule Technologies: A Cool Shot at a MultibaggerBy Thomas Hughes | June 9, 2026BTAI, APRE, OMER, and RAPT Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.80 -0.02 (-2.04%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$0.80 -0.01 (-0.79%) As of 06/30/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.BioXcel Therapeutics NASDAQ:BTAI$1.41 +0.01 (+0.71%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$1.40 -0.01 (-0.64%) As of 06/30/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Omeros NASDAQ:OMER$9.51 -0.40 (-4.04%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$9.50 -0.01 (-0.13%) As of 06/30/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Rapt Therapeutics NASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
